We are happy to report that Allergan has acquired the OcuMend® product. Find the latest at www.OcuMend.com.
Cearna will continue to develop Arnica products for the reduction of bruising, pain, swelling and inflammation. We intend to conduct the largest Arnica clinical trial with the top research universities in the country. Stay tuned for further developments.
Cearna’s patented topical arnica gel pads dramatically reduce or prevents bruising, swelling and pain due to most acute injuries. After licensing our technology to Allergan/Abbvie for the cosmetic plastic and dermatology uses, we are now developing a consumer product for the reduction of swelling, pain and bruising due to sprains, strains and minor accidents.
Cearna seeks to be a good corporate citizen and we value every person on our team. Our company DNA includes the following:
- Empathy for patients, customers, and coworkers drives excellence.
- Doing the right thing rather than the easy thing
- ROI of time, money and energy drives priorities
- Comfort with experimentation, change, and ambiguity.
Statistically significant reduction in bruising: 18 bruises were induced by dropping a 3-pound, 2-foot bar 20 inches onto the skin. The bruises after treatment with an inactive placebo gel pad were compared to those after treatment with Cearna technology. Cearna technology was found to be statistically significant in reducing bruising (P=.0000005) with a mean bruising of 0.84 for Cearna technology compared to 6.91 for the inactive gel on a 10 point scale
Clinically Proven Ultra-Penetrating Nanotechnology
Cearna’s patented arnica technology deploys novel HASA nanostructures. Cearna’s technology is clinically proven to reduce bruising, pain and swelling.
San Diego, CA